Publication:
Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

cris.virtualsource.author-orcidc884f270-3584-466b-b5c5-3217eb95f2c3
dc.contributor.authorMeyrat, P
dc.contributor.authorSafroneeva, Ekaterina
dc.contributor.authorSchoepfer, A M
dc.date.accessioned2024-10-11T13:30:33Z
dc.date.available2024-10-11T13:30:33Z
dc.date.issued2012
dc.description.abstractWhile rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.
dc.description.numberOfPages10
dc.description.sponsorshipInstitut für Sozial- und Präventivmedizin (ISPM)
dc.identifier.doi10.7892/boris.14037
dc.identifier.isi000310871000009
dc.identifier.pmid23066911
dc.identifier.publisherDOI10.1111/apt.12087
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/84107
dc.language.isoen
dc.publisherWiley-Blackwell
dc.publisher.placeOxford
dc.relation.ispartofAlimentary pharmacology & therapeutics
dc.relation.issn0269-2813
dc.relation.organizationDCD5A442BECFE17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleRifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage93
oaire.citation.issue11-12
oaire.citation.startPage1084
oaire.citation.volume36
oairecerif.author.affiliationInstitut für Sozial- und Präventivmedizin (ISPM)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.description.ispublishedpub
unibe.eprints.legacyId14037
unibe.journal.abbrevTitleALIMENT PHARM THER
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Meyrat AlimentPharmacolTher 2012.pdf
Size:
359.62 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections